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Abstract
Background: The enzyme indoleamine 2,3-dioxygenase (IDO) exerts an well established immunosuppressive function in
cancer. IDO is expressed within the tumor itself as well as in antigen-presenting cells in tumor-draining lymph nodes, where
it promotes the establishment of peripheral immune tolerance to tumor antigens. In the present study, we tested the
notion whether IDO itself may be subject to immune responses.
Methods and Findings: The presence of naturally occurring IDO-specific CD8 T cells in cancer patients was determined by
MHC/peptide stainings as well as ELISPOT. Antigen specific cytotoxic T lymphocytes (CTL) from the peripheral blood of
cancer patients were cloned and expanded. The functional capacity of the established CTL clones was examined by chrome
release assays. The study unveiled spontaneous cytotoxic T-cell reactivity against IDO in peripheral blood as well as in the
tumor microenvironment of different cancer patients. We demonstrate that these IDO reactive T cells are indeed peptide
specific, cytotoxic effector cells. Hence, IDO reactive T cells are able to recognize and kill tumor cells including directly
isolated AML blasts as well as IDO-expressing dendritic cells, i.e. one of the major immune suppressive cell populations.
Conclusion: IDO may serve as an important and widely applicable target for anti-cancer immunotherapeutic strategies.
Furthermore, as emerging evidence suggests that IDO constitutes a significant counter-regulatory mechanism induced by
pro-inflammatory signals, IDO-based immunotherapy holds the promise to boost anti-cancer immunotherapy in general.
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Introduction
Recent advances in the understanding of the interplay between
cancer cells and cells of the immune system demonstrated the
capacity of the immune system to recognize and destroy neoplastic
cells; nevertheless, despite the fact that neoplastic transformation is
associated with the expression of immunogenic antigens, the
immune system often fails to respond effectively to these antigens.
Thus, the immune system becomes tolerant towards these antigens
[1]. There is a general consensus, that this acquired state of
tolerance must be overcome for cancer immunotherapy to succeed.
The biological role of Indoleamine 2,3-dioxygenase (IDO) in the
immune system is still a subject of active investigation. For example,
endogenous IDO has been implicated as one mechanism by which
maternal tolerance toward the fetus is maintained [2]. Likewise,
IDO can mediate suppression of T-cell immunity to MHC-
mismatched liver allografts [3]. Furthermore, IDO control T-cell
responses to autoimmune disorders, and regulates the severity of a
variety of experimental autoimmune disorders [4,5]. Thus, several
lines of evidence indicate that IDO is a major component to
maintain the homeostasis of the immune system which, however,
also contributes to tumor-induced tolerance. The expression and
activation of IDO creates a tolerogenic milieu in the tumor and the
tumor-draining lymph nodes (LN) either via direct suppression of T
cells by degradation of the essential amino acid tryptophan or via
enhancement of local regulatory T-cell (Treg) -mediated immuno-
suppression. With respect to the former, some of the biological
effects of IDO are mediated through local depletion of tryptophan,
whereas others are mediated via immunomodulatory tryptophan
metabolites [6,7].
IDO can be expressed within the tumor by tumor cells as well as
tumor stromal cells, where it inhibits the effector phase of immune
responses. In this setting, IDO is believed to inhibit the effector
phase of the immune response [8,9]. In a murine model it was
observed that tumor cells transfected with IDO become resistant
to immune eradication, even in mice in which a fully protective
immune response had been established by immunization [9]. Most
importantly, in the clinical situation it was repeatedly observed,
that expression of IDO in tumor cells is associated with an
impaired prognosis [10,11].
Additionally, IDO-expressing antigen-presenting cells (APC) are
present in tumor-draining LN, where they are believed to create a
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+
plasmacytoid dendritic cells (DC) isolated from tumor-draining LN
mediate profound immune suppression and T-cell anergy in vivo
[12–14]; plasmacytoid DC from normal LN and spleen do not
express IDO. It should be noted that very few cells constitutively
express IDO in normal lymphoid tissue except in the gut. This
implies that the DC in tumor-draining LN, which constitutively
express IDO must receive a stimulus which is related to the
presence of the tumor. This stimulus is believed to be delivered by
activated Tregs migrating from the tumor to the draining LN.
Tregs have been shown to induce IDO via cell-surface expression
of CTLA-4 [15]. The induction of IDO converts the tumor-
draining LN from an immunizing into a tolerizing milieu. Indeed,
when IDO
+ DC are injected in vivo, they create suppression and
anergy in antigen-specific T cells in the LN draining the injection
site [14,16]. Hence, IDO is a critical cellular factor contributing to
immune suppressive and tolerogenic mechanism in cancer.
Consequently, IDO has become a very attractive target for the
design of new anticancer drugs and several IDO inhibitors are
currently being investigated [17,18]. However, to date the
possibility to harness the immune system to target IDO-expressing
cells has not been explored. This is particular surprising since
IDO-expressing cells antagonizes the desired effects of other
immunotherapeutic approaches and a combination of IDO- and
tumor-targeting immunotherapies should be highly synergistic. In
the present study, we provide evidence for the immunogenicity of
IDO by demonstrating the presence of spontaneous cytotoxic
immune responses against IDO-expressing cells in cancer patients.
Methods
Patients
Peripheral Blood Mononuclear Cells (PBMC) were collected
from cancer patients (renal cell carcinoma, melanoma, and breast
cancer) and healthy controls. Blood samples were drawn a
minimum of four weeks after termination of any kind of anti-
cancer therapy. The majority of renal cell carcinoma patients had
previously been treated with IL2 and IFN-a, most melanoma
patients had received high dose IL2 and IFN-a, while all breast
cancer patients were pre-treated with several kinds of chemother-
apy, (e.g. epirubicin, docetaxel, cabecitabine), trastuzumab, and/
or endocrine therapy. PBMC were isolated using Lymphoprep
separation, HLA-typed (Department of Clinical Immunology,
University Hospital, Copenhagen, Denmark) and frozen in FCS
with 10% DMSO. The protocol was approved by the Scientific
Ethics Committee for The Capital Region of Denmark and
conducted in accordance with the provisions of the Declaration of
Helsinki. Written informed consent from the patients was obtained
before study entry.
Peptides
Epitopes from IDO were predicted using the ‘‘Database
SYFPEITHI’’ [19] in combination with manual examination of
the protein sequence for MHC class I anchor residues. Eleven
synthetic 9mer and 10mer peptides were produced: IDO1 (IDO54-
62; QLRERVEKL), IDO2 (IDO164-172; (FLVSLLVEI), IDO3
(IDO195-203; TLLKALLEI), IDO4 (IDO41-49; FIAKHLPDL),
IDO5 (IDO199-207; ALLEIASCL), IDO6 (IDO320-328;
VLSKGDGL), IDO7 (IDO383-391; DLMNFLKTV), IDO8
(IDO275-283; VLLGIQQTA), IDO9 (IDO101-109; KVLPRNIAV),
IDO10 (IDO61-70; KLNMLSIDHL), and IDO11 (IDO341-350;
SLRSYHLQIV). The peptides were dissolved in DMSO (final
concentration 10 mM) or distilled water (final concentration
2 mM). The HLA-A2 high affinity binding epitope HIV-1
pol476-484 (ILKEPVHGV) was used as irrelevant control. The
HLA-A2 restricted Epstein - Barr virus peptide EBVBMLF1280-288
(GLCTLVAML) was used as control.
Assembly assay for peptide binding to MHC class I
molecules
The binding affinity of the synthetic peptides (Genscript) to
HLA-A2 molecules, metabolically labelled with [
35S]-methionine,
was measured in the assembly assay, as described previously
[20,21]. The assay is based on peptide-mediated stabilization of
empty HLA-molecules released upon cell lysis, from the TAP-
deficient cell line T2. Stably folded HLA-molecules were immune-
precipitated by using the HLA class I specific, conformation
dependent monoclonal antibody (mAb) W6/32 and separated by
isoelectric focusing (IEF) gel electrophoresis. Major histocompat-
ibility complex (MHC) heavy-chain bands were quantified using
the ImageGauge Phosphoimager program (FUJI Photo Film,
Carrolton, TX). The intensity of the band is directly related to the
amount of peptide-bound class I MHC complex recovered during
the assay. Subsequently, the extent of stabilization of HLA-A2 is
directly related to the binding affinity of the added peptide. The
recovery of HLA-A2 was measured in presence of 100, 10, 1, 0.1
and 0.01 mM of the relevant peptide. The C50 value was
calculated for each peptide as the peptide concentration required
for half maximal stabilization of HLA-A2.
ELISPOT assay
The ELISPOT assay was used to quantify peptide epitope-specific
IFN-c releasing effector cells as described previously [22]. In some
experiments PBMC were stimulated once in vitro with peptide prior to
analysis as described [23] to extend the sensitivity of the assay. After 7
days in culture with peptide and 40 U/ml IL-2 (PeproTech), cells
were counted and analyzed in IFN-c ELISPOT. Briefly, nitrocellu-
lose bottomed 96-well plates (MultiScreen MAIP N45; Millipore)
were coated overnight with IFN-ccapture mAb (Mabtech). The wells
were washed, blocked by X-vivo medium and the effector cells were
added in duplicates at different cell concentrations, with or without
10 mM peptide. The plates were incubated overnight. The following
day, medium was discarded and the wells were washed prior to
addition of biotinylated secondary Ab (Mabtech). The plates were
incubated at room temperature (RT) for 2 hours, washed, and
Avidin-enzyme conjugate (AP-Avidin; Calbiochem/Invitrogen Life
Technologies) was added to each well. Plates were incubated at RT
for 1 hour and the enzyme substrate NBT/BCIP (Invitrogen Life
T e c h n o l o g i e s )w a sa d d e dt oe a c hw e l la n di n c u b a t e da tR Tf o r5 –
10 min. Upon the emergence of dark purple spots, the reaction was
terminated by washing with tap water. The spots were counted using
the ImmunoSpot Series 2.0 Analyzer (CTL Analyzers).
Flow cytometry
For tetramer stainings, PBMC from cancer patients and healthy
donors as well as tumor infiltrating lymphocytes (TIL) from cancer
patients were stimulated once in vitro with peptide, or analysed
directly ex vivo. The CD8 T cells were isolated from PBMC using
the Dynal CD8 negative isolation kit (Dynal Biotech) at day 7. The
resulting T-cell cultures were stained with PE coupled tetramers,
followed by antibody staining with an appropriate combination of
the fluorochrome-coupled mAbs: CD8-allophycocyanin/APC-
Cy7, CD3-FITC, CD45RO-FITC, CD45RA-PE-Cy5 and
CD28-allophycocyanin (BD Bioscience). For comparison, cells
were stained with appropriate isotype controls. Tetramers were
prepared using the MHC-peptide exchange technology [24] as
described in [25]. Tetramer stainings were performed in PBS +2%
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were performed in PBS +2% FCS, for 20 min., 4uC, in the dark.
The MHC tetramer complexes used were: HLA-A2/IDO5
(ALLEIASCL) and HLA-A2/HIV-1 pol476–484 (ILKEPVHGV).
The samples were analyzed on BD FACS Aria, using DIVA
software (BD Biosciences).
Cancer cells were examined for HLA-A2 expression using flow
cytometry. Cells were stained with a fluorochrome-coupled HLA-
A2 mAb (BD Bioscience). For comparison, cells were stained with
an isotype matched control. The samples were analyzed on BD
FACS Aria, using DIVA software (BD Biosciences). Assuming
normality, HLA-A2 expression was given by a one-tailed two
sampled t-test comparing MFIHLA-A2 and MFIIsotype control, where
MFI is the Mean Fluorescence Intensity. For p-values ,0.05
(significance level) cells were defined HLA-A2
+. The fold of
expression was defined as MFIHLA-A2/MFIIsotype control.
Intracellular protein staining
PBMC, DC, and cancer cells were examined for intracellular
IDO expression using flow cytometry. After fixation and
permeabilization (Cytofix/Cytoperm, BD), cells were stained with
anti-IDO antibody (Millipore Corporation). For comparison, cells
were stained with an isotype matched control (Millipore
Corporation). After incubation, cells were washed twice with
Perm/Washbuffer (BD) before staining with a FITC-labeled
secondary antibody (DAKO). The samples were analyzed on
BD FACS Aria, using DIVA software (BD Biosciences). Assuming
normality, intracellular IDO expression was given by a one-tailed
two sampled t-test comparing MFIIDO and MFIIsotype control, where
MFI is the Mean Fluorescence Intensity. For p-values ,0.05
(significance level) cells were defined IDO
+. The fold of expression
was defined as MFIIDO/MFIIsotype control.
Dendritic cells (DC)
DC were generated from PBMC by adherence on culture dishes
at 37uC for 60 min in RPMI-1640 enriched with 10% human AB
serum. Adherent monocytes were cultured in RPMI-1640
supplemented with 10% human AB serum in the presence of
IL-4 (1000 U/ml) and GM-CSF (250 U/ml) for 6 days. DC were
matured by addition of IL-1b (1000 U/ml), IL-6 (1000 U/ml),
TNF-a (1000 U/ml), and PGE2 (1 mg/ml).
Establishment of antigen specific T- cell cultures and
clones
PBMC from cancer patients were stimulated with irradiated (25
Gy), IDO5-loaded autologous DC (PBMC:DC ratio =3610
6:36
10
5), with 3 mg/ml b2m, 20 U/ml IL-12 (PeproTech), and 40 U/
ml IL-7 (PeproTech). The cultures were stimulated every 10 days
with irradiated autologous DC (26) followed by irradiated PBMC
(26), with 40 U/ml IL-2 (PeproTech). After one month, growing
cultures were tested for specificity for IDO5 in a standard
51Cr-
release assay. PBMC from specific cultures were cloned by limiting
dilution in the presence of 10
6/ml irradiated (25 Gy) IDO5-loaded
PBMC, and 120 U/ml IL-2. Every 3-4 days 50 ml fresh media
were added containing IL-2 to a final concentration of 120 U/ml.
Growing clones were expanded using IDO5-loaded PBMC
(5610
4 cells/well) and 120 U/ml IL-2. After expansion the clones




51Cr-release assays for CTL-mediated cytotoxic-
ity was carried out as described elsewhere [26]. Target cells were
T2-cells, in vitro generated autologous immature DC (iDC) and
matured DC (mDC), in vitro generated allogeneic HLA-A2
+ iDC
and mDC, autologous ex vivo isolated monocytes, T cells and B




(MACS)), the natural killer target cell line K562, ex vivo enriched
HLA-A2
+ AML-blasts (B and T cells were depleted from the bone
marrow of AML patients using CD19
+ and CD3
+ microbeads
(MACS)), the breast cancer cell lines CAMA-1 and MDA-MB-
231, as well as the colon cancer cell lines HCT-116 and SW480
(all available at the American Type Culture Collection (ATCC)),
and FM55M [27]. Lysis were blocked using the HLA specific mAb
W6/32 (2 mg/100 ml) [28]. In some assays, target cells were
treated with 100 U/ml IFN-c for 2 days.
Down-regulation of IDO in cancer cells
Human SW480 cancer cells were transfected with indicated
short hairpin RNA (ShRNA) plasmids obtained from SuperArray
using FuGene6 (Roche) according to manufacturers instructions.
Cells were lysed directly in LSB buffer (Sigma). The LSB lysates
were boiled for 5 min. and loaded on 10% precast protein gels
(BioRad). Proteins were electro transferred to a PVDF membrane
(Millipore Corporation) by a semidry transfer method and probed
with indicated antibodies according to manufacturers instructions.
Blots were developed with the ECL system obtained from
Amersham and a CCD camera (LAS-1000, Fujifilm). Following
antibodies were used: anti-Cdk7 (MO-1) (Santa Cruz) and anti-
IDO (Millipore Corporation).
Statistical analysis
Statistical analysis was performed on data on intracellular IDO
staining. Assuming normality, intracellular IDO expression was
given by a one-tailed two sampled t-test comparing MFIIDO and
MFIIsotype control, where MFI is the Mean Fluorescence Intensity.
For p-values ,0.05 (significance level) cells were defined IDO
+.
The fold of expression was defined as MFIIDO/MFIIsotype control.
HLA-A2 expression was determined using the same approach.
Results
IDO-derived HLA-A2-restricted T-cell epitopes
Eleven IDO-derived peptides were selected from the main
HLA-A2 specific anchor residues and subsequently synthesized
[29]. Using the ELISPOT IFN-c secretion assay, we then
examined PBMC from cancer patients and healthy individuals
for the presence of specific T-cell responses against these IDO-
derived peptides. This approach has previously proved to be
highly effective for identifying tumor specific cytotoxic T-
lymphocytes (CTL) in cancer patients [22,30,31]. Thus, PBMC
from HLA-A2
+, late stage cancer patients (breast cancer,
melanoma and renal cell carcinoma) were stimulated once with
the different peptides in vitro before examination by ELISPOT.
This procedure was chosen to extend the sensitivity of the
ELISPOT as described [22,32]. ELISPOT responses were
detected against IDO2 (IDO164-172; FLVSLLVEI) (Fig. 1b),
IDO6 (IDO320-328; VLSKGDGL) (Fig. 1c) and, especially,
IDO5 (IDO199-207; ALLEIASCL) (Fig. 1a). To this end, PBMC
from a larger number of cancer patients were examined for
reactivity against IDO2 and IDO6, since these responses were less
frequent compared to IDO5. As control, we examined PBMC
from healthy individuals for reactivity against these three IDO
derived peptides. No spontaneous responses could be detected
against any of the IDO-derived peptides in any of the healthy
controls. A BLAST search of the amino acid sequences of these
The Immune System Strikes Back
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only prevalent in the IDO protein.
Detection of IDO-reactive HLA-A2-restricted T cells in
cancer patients
The apparently most immunogenic IDO-derived peptide, i.e.
IDO5, was examined for its binding affinity to HLA-A2 by
comparison with a HLA-A2 high affinity positive control epitope,
i.e. HIV-1 pol476-484 (ILKEPVHGV), by the assembly assay
(Table 1). For comparison, the HLA-A2 binding affinity of IDO2
and IDO6 were analyzed as well. C50 values were estimated for
each peptide as the peptide concentration required for half
maximal stabilization of HLA-A2. Notably, IDO5 bound HLA-A2
even better than the high-affinity control epitope, whereas IDO2
and IDO6 bound HLA-A2 with intermediate affinity compared to
the control epitope (Table 1). The high binding affinity of IDO5 to
HLA-A2 enabled us to make stable HLA-A2/IDO5 tetramers,
which were used to detect IDO-reactive CTL by flow cytometry.
This analysis clearly confirmed the presence of IDO5-reactive
CD8 T cells in the blood of HLA-A2
+ cancer patients (Fig. 2).
Figure 2a illustrates an example of an IDO5-specific T cell
response after in vitro stimulation in a renal cell carcinoma patient
with an HIV-1 tetramer-complex used as control. While the
frequency of IDO-reactive T cells are markedly increased by in
vitro stimulation, IDO-reactive T cells were readily detectable ex
vivo in selected patients (Fig. 2b): In the three patients with
strongest responses after in vitro stimulation, a respective reactivity
was also detected ex vivo. Overall, PBMC from 7 HLA-A2
+ healthy
individuals and 11 HLA-A2
+ patients were analyzed. No IDO-
reactive T cells could be detected in any of the healthy donors
(Fig. 2b). The ex vivo stainings of IDO-reactive T cells showed that
naturally occurring IDO5-specific T cells have a CD45RA
-CD28
+
central/effector memory phenotype [33]. An example of such an
ex vivo phenotype staining of IDO5 tetramer gated cells is shown in
figure 2c. As a comparison the sample were stained with isotype
matched controls. Next, we examined the presence of IDO5-
specific T cells in IL-2 treated TIL cultures from HLA-A2
+
melanoma and head and neck cancer patients by tetramer
stainings. As illustrated in figure 2d IDO5-specific T cells could
readily be detected among the TIL. Overall, 4 of the 5 analyzed
patients had detectable IDO5-specific T cells. The percentage of
IDO5-specific T cells among the TIL ranged from 0.05 to 0.1% of
the total number of CD8 T cells. Likewise, IDO5-specific T cells
in TIL cultures from melanoma and head and neck cancer
patients could be detected in ELISPOT (data not shown). To
control the specificity of the HLA-A2/IDO5 tetramer we stained
an IDO5-specific T-cell clone. The HLA-A2/IDO5 tetramer did
efficiently stain the IDO5-specific T-cell clone, whereas the T-cell
Figure 1. HLA-A2-restricted T-cell responses against IDO as
measured by IFN-c ELISPOT. PBMC from healthy donors, breast
cancer patients, melanoma patients, and renal cell carcinoma patients
were analyzed. All individuals were HLA-A2
+. The peptides IDO5 (IDO199-
207; ALLEIASCL) (a), IDO2 (IDO164-172; FLVSLLVEI) (b), and IDO6 (IDO320-
328; VLSKGDGL) (c), were examined. T cells were stimulated once in vitro
with peptide before being plated at 4610
5 cells per well in duplicates
either without or with the relevant IDO peptide. The average number of
IDO-specific spots (after subtraction of spots without added peptide)
was calculated per 4610
5 PBMC for each patient (white triangle). (a),
Top, Example of an ELISPOT response against IDO5 (IDO199-207;
ALLEIASCL) in PBMC from a breast cancer patient.
doi:10.1371/journal.pone.0006910.g001
Table 1. HLA-A2 binding affinity of selected IDO-derived
peptides.
Peptide Sequence C50 (mmol/L)
*
HIV-1 pol 476-484 ILKEPVHGV 0.3
IDO2 (IDO164-172) FLVSLLVEI 30.0
IDO5 (IDO199-207) ALLEIASCL 0.2
IDO6 (IDO320-328) VLSKGDGL 3.5
*The C5 value is the peptide concentration required for half maximal
stabilization of HLA-A2.
doi:10.1371/journal.pone.0006910.t001
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tetramer (Fig. 2e).
Having identified patients hosting responses against the IDO5
peptide, we used PBMC from such patients to generate CTL bulk
cultures against this peptide in vitro. PBMC were stimulated by
autologous IDO5-pulsed DC. After four rounds of stimulation, the
peptide specificity was tested in standard
51Cr-release assays. Bulk
cultures were generated from three different cancer patients. Cells
from two of these bulk cultures lysed TAP-deficient T2-cells pulsed
with IDO5 peptide. To analyze the lytic capacity of IDO-specific
T cells in more detail, CTL clones were established from one of
these bulk cultures by limiting dilution cloning. After a short
expansion period, the specificity of the growing clones was
analyzed in standard
51Cr-release assays. Of thirty three T-cell
clones displaying an IDO-specific lytic capacity, four clones were
selected for further expansion due to a superior growth rate. A
representative T-cell clone is depicted in figure 3a: the T-cell clone
RBS35 effectively killed IDO5-pulsed T2-cells whereas T2-cells
pulsed with a irrelevant peptide (HIV-1 pol476-484 (ILKEPVHGV))
were not lysed (Fig. 3a).
Killing of tumor targets by IDO-specific T cells
Importantly, RBS35 killed not only peptide pulsed T2-cells but
also the HLA-A2
+/IDO
+ colon cancer cell line SW480 with high
efficacy (Fig. 3b). In contrast, RBS35 did not lyse the HLA-A2
+/
IDO
- colon cancer cell line HCT-116 (Fig. 3b). HLA-restriction of
Figure 2. Tetramer analysis of IDO5-specific T cells. (a), An example of IDO5-specific, CD8 T-cell enriched PBMC from a renal cell carcinoma
patient visualised by flow cytometry staining using the tetramer complex HLA-A2/IDO5-PE, and CD8-allophycocyanin after one in vitro stimulation
with IDO5 peptide. As a negative control, cells were stained with the tetramer complex HLA-A2/HIV-1 pol476–484-PE, and CD8-allophycocyanin. (b),
PBMC from healthy donors or from patients with breast cancer, melanoma cancer or renal cell carcinoma were stained with the tetramer complex
HLA-A2/IDO5 or HLA-A2/HIV-1 pol476–484 and analyzed by flow cytometry either ex vivo or after one in vitro peptide stimulation. The dotted lines
illustrate that IDO5-tetramer positive cells are detectable both ex vivo and in vitro in the same patients. (c), An example of CD45RA and CD28
phenotype analysis of IDO5-tetramer/CD8 gated cells from CD8 T-cell enriched PBMC from a renal cell carcinoma patient visualised ex vivo by flow
cytometry. For comparison, the cells were stained with isotype matched controls (d), An example of an IL-2 expanded TIL culture from a melanoma
patient visualised by flow cytometry staining using the tetramer complex HLA-A2/IDO5-PE, and CD8-APC-Cy7. As a negative control, the TIL were
stained with the tetramer complex HLA-A2/HIV-1 pol476–484-PE, and CD8-APC-Cy7. (e), As a positive control of the IDO5 tetramer, an IDO5-specific T-
cell clone (RBS35) was stained with the HLA-A2/HIV-1 pol476–484-PE and HLA-A2/IDO5-PE tetramers.
doi:10.1371/journal.pone.0006910.g002
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specific mAb W6/32, which completely abolished lysis of the
SW480 target cells (Fig. 3b). A number of cancer cell lines were
examined for IDO expression by intracellular protein staining
followed by FACS analysis [34]. The colon cancer cell line
SW480, the melanoma cell line FM55M, the breast cancer cell
lines CAMA-1 and MDA-MB231 as well as directly enriched
AML-blasts were all IDO
+. Only the colon cancer cell line HCT-
116 was IDO
-. Representative examples of IDO stainings are
illustrated in histograms in figure 3c.
Next, we demonstrated that the HLA-A2
+/IDO
+ melanoma
cell line FM55M was killed by RBS35 (Fig. 4a). Cold targeted
inhibition assays using unlabeled T2-cells pulsed with the IDO5
(10 mM) peptide confirmed the HLA-A2/peptide-specificity of the
killing: The addition of cold (unlabeled) IDO5-pulsed T2-cells
completely abrogated the killing of FM55M melanoma cells,
whereas the addition of cold T2-cells pulsed with an irrelevant
peptide (HIV-1 pol476-484) did not have an effect on the killing of
FM55M (Fig. 4a). No cytotoxicity was observed against the NK-
cell target cell line K562 (Fig. 4a).
Furthermore, we tested the ability of RBS35 to lyse human
AML-blasts enriched directly ex vivo from the bone-marrow of
AML patients. For this purpose, we depleted T cells (CD3
+) and B
cells (CD19
+) from the bone marrow of AML patients; the highly
enriched AML-blasts (CD3
-, CD19
-) were subsequently used as
target cells in a
51Cr-release assay. We enriched AML blasts from
six patients (5 HLA-A2
+ patients and 1 HLA-A2
- patient). All
AML blasts expressed IDO (data not shown). RBS35 efficiently
lysed the HLA-A2
+ leukemia cells in an HLA-dependent manner,
while HLA-A2
- leukemia cells were not lysed (Fig. 4b). We did not
find a correlation between the amount of IDO expression in the
AML blasts and the percentage of lysis (data not shown).
To illustrate the representative killing of tumor targets by
RBS35 the killing of SW480 by a polyclonal, IDO5-specific bulk
culture as well as by three other T-cell clones (RBS26, RBS31,
RBS46) are shown in figure 4c and figure 4d. The T cell clones
had distinct TCR as verified by TCR Clonotype Mapping (data
not shown). Similar to RBS35, none of the clones (RBS26, RBS31,
RBS46) lysed the HLA-A2
+/IDO
- colon cancer cell line HCT-116
(Fig. 4d).
Finally, we examined the killing of the HLA-A2
+ breast cancer
cell lines CAMA-1 and MDA-MB-231. The CAMA-1 cell line was
killed by RBS35, whereas MDA-MB-231 was not recognized by
RBS35 (Fig. 5a). IFN-c treatment increased the expression of IDO
Figure 3. Specificity and functional capacity of IDO5-specific T-cells assayed by
51Cr-release assays. (a), Lysis of T2-cells pulsed with IDO5
peptide or an irrelevant peptide (the HLA-A2 high affinity binding epitope HIV-1 pol476-484 (ILKEPVHGV)) by a T-cell clone (RBS35). (b), Specific lysis by
RBS35 of the HLA-A2
+/IDO
+ colon cancer cell line SW480 without or with the addition of the HLA-class I specific antibody W6/32, and lysis of the HLA-
A2
+/IDO
-colon cancer cell line HCT-116. All assays were performed in different E:T ratios. (c) Histograms showing intracellular IDO expression in cancer
cell lines. Data are representative of 3 experiments. Intracellular IDO expression was given by a one-tailed two sampled t-test comparing MFIIDO (dark
histograms) and MFIIsotype control (light histograms), where MFI is the Mean Fluorescence Intensity. Left: HCT-116 (p=0.300). Right: SW480 (p=0.002).
doi:10.1371/journal.pone.0006910.g003
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PLoS ONE | www.plosone.org 6 September 2009 | Volume 4 | Issue 9 | e6910and HLA-A2 in both cell lines. This is exemplified for CAMA-1 in
figure 5b and c. In agreement with this, IFN-c treatment increased
the killing by RBS35 of CAMA-1 and introduced killing of the
MDA-MB-231 cells (Fig. 5a).
Additionally, using IDO ShRNA we down-regulated IDO
protein expression in the human SW480 colon cancer cell line and
thereby rescue these tumor cells from being killed by the
polyclonal IDO-specific bulk culture, whereas cells transfected
with irrelevant control ShRNA were killed (Fig. 5d). This down-
regulation was visualized by intracellular protein stainings. These
stainings confirmed that the use of IDO ShRNA reduced the level
of IDO protein expression in the cells (Fig. 5e).
Killing of dendritic cells by IDO-specific T cells
IDO expression is not restricted to tumor and tumor stroma cells,
but can also be induced in immune cells. Thus, as the next and even
more important step we addressed the question whether IDO-
expressing DC would also be susceptible to killing by IDO-reactive
CTL. To test this notion, we generated autologous DC from the same
donors from whom the CTL clones had been generated; the DC were
matured by addition of a standard maturation cocktail consisting of IL-
1b,I L - 6 ,T N F - a,a n dP G E 2 [35]. RBS35 effectively killed the in vitro
matured DC (mDC). In contrast, autologous IDO
- immature DC
(iDC) were not killed by RBS35 (Fig. 6a). Moreover, we examined the
recognition of allogenic IDO
+mDC and IDO
-iDC from an HLA-A2
+
Figure 4. Specificity and functional capacity of IDO5-specific T cells assayed by
51Cr-release assays. (a), Lysis by the IDO5-specific T-cell
clone (RBS35) of the HLA-A2
+/IDO
+ melanoma cell line FM55M without and with the addition of cold T2-cells pulsed with IDO5 peptide or an
irrelevant peptide (HIV-1 pol476-484) (inhibitor to target ratio =20:1), and NK cell activity of RBS35 examined using the natural killer cell line K562 as
target cells. (b), Lysis by RBS35 of AML-blasts enriched from 5 HLA-A2
+ AML patients and 1 HLA-A2
- AML patient. B cells and T cells were depleted
from the bone marrow of the AML patients using CD19
+ and CD3
+ microbeads, respectively. The highly enriched AML-blasts were used as target cells
with or without the addition of the HLA-class I specific antibody W6/32. (c), Lysis of T2-cells pulsed with IDO5 peptide or an irrelevant peptide (HIV-1
pol476-484), and lysis of the HLA-A2
+/IDO
+ colon cancer cell line SW480 by an IDO5-specific T-cell bulk culture. (d), Lysis of the HLA-A2
+/IDO
+ colon
cancer cell line SW480 and HLA-A2
+/IDO
- colon cancer cell line HCT-116 by three different IDO5-specific T-cell clones (RBS26 (white triangle), RBS31
(black triangle), RBS46 (grey triangle)) assayed by
51Cr-release assay. All assays were performed in different E:T ratios.
doi:10.1371/journal.pone.0006910.g004
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allogenic IDO
-iDC were not killed (Fig. 6a). In figure 6b it is illustrated
that mDC express IDO in contrast to iDC. Next, we tested the ability
of RBS35 to lyse autologous monoctyes, T cells and B cells. For this
purpose, we isolated CD14
+ monocytes, CD3
+ Tc e l l sa n dC D 1 9
+ B
cells directly ex vivo from IDO
+ PBMC. The isolated cells were




+ Tc e l l sa n dC D 1 9
+ B cells were not lysed by
RBS35 (Fig. 6c). IFN-c treatment introduced killing of the CD14
+
monocytes, but not of the T and B cells (Fig. 6c).
Finally, we sat up an in vitro model to examine if IDO specific T
cells enhance immune responses by depleting IDO-expressing
suppressive cells. Hence, cultures of PBMC, with and without
IDO5 specific T cells, were treated with IFN-c to increase the
immune activity as well as IDO expression in the cultures. Five
days later we examined the immune reactivity against the HLA-
A2 restricted immunodominant epitope from EBV BMLF1280-288
(GLCTLVAML) in the cultures. Although the overall cell number
was the same in the cultures the reactivity against the EBV peptide
was higher in the cultures with IDO5-specific T cells (figure 6d).
Next, we scrutinized if the addition of IDO specific T cells
increased the immune reactivity to an extent that allowed
detection of EBV responses in an ELISPOT with only 10
4
PMBC; far below the normal detection limit. Indeed, we could
detect a clear EBV response even at this low concentration of
PBMC (Fig. 6d). As expected we could not detect any EBV
response at this low cell concentration in the culture without IDO5
specific T cells (Fig. 6d).
Discussion
IDO has a critical immunosuppressive function in cancer. In the
present study, we set out to examine if IDO itself may serve as
target for immune responses, which may be exploited for immune
therapy. By following a ‘reverse immunology’ approach, we
identified HLA-A2 peptides within the IDO protein to which
Figure 5. Functional capacity of IDO5-specific T cells to kill cancer cell lines treated with IFN-c for up-regulation of IDO, or treated
with IDO ShRNA for down-regulation of IDO. (a), Lysis by the IDO5-specific T-cell clone (RBS35) of the HLA-A2
+ breast cancer cell lines CAMA-1
(right) and MDA-MB-231 (left) before and after IFN-c treatment. (b), Histograms showing intracellular IDO expression in CAMA-1 before and after IFN-c
treatment. Data are representative of 3 experiments. Intracellular IDO expression was given by a one-tailed two sampled t-test comparing MFIIDO
(dark histograms) and MFIIsotype control (light histograms), where MFI is the Mean Fluorescence Intensity. The fold of expression was defined as MFIIDO/
MFIIsotype control. Top: CAMA-1 (p=0.020 and MFIIDO/MFIIsotype control =2.3). Bottom: CAMA-1 + IFN-c treatment (p=0.004 and MFIIDO/MFIIsotype control
=3.5). (c), Histograms showing HLA-A2 expression in CAMA-1 before and after IFN-c treatment. Data are representative of 3 experiments. HLA-A2
expression was given by a one-tailed two sampled t-test comparing MFIHLA-A2 (dark histograms) and MFIIsotype control (light histograms). The fold of
expression was defined as MFIHLA-A2/MFIIsotype control. Top: CAMA-1 (p=0.004 and MFIHLA-A2/MFIIsotype control =43.7). Bottom: CAMA-1 + IFN-c
treatment (p=0.002 and MFIIDO/MFIHLA-A2 =141.2). (d), Lysis of the colon cancer cell line SW480 transfected with IDO ShRNA for down-regulation of
IDO protein expression by an IDO5-specific T-cell bulk culture. As a positive control, SW480 cells transfected with control ShRNA were used as target
cells. All assays were performed in different E:T ratios. (e), Histograms showing intracellular IDO expression in SW480 transfected with control ShRNA
(p=0.001 and MFIIDO/MFIIsotype control =4.8) (top) and IDO ShRNA (p=0.040 and MFIIDO/MFIIsotype control =2.1) (bottom).
doi:10.1371/journal.pone.0006910.g005
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PLoS ONE | www.plosone.org 8 September 2009 | Volume 4 | Issue 9 | e6910Figure 6. Functional capacity of an IDO5-specific T-cell clone (RBS35) to kill immune cells assayed by
51Cr-release assays. (a), Left:
Lysis of autologous in vitro immatured and matured DC. Right: Lysis of allogeneic HLA-A2
+ in vitro immatured and matured DC. All assays were
performed in different E:T ratios. (b), Histograms showing intracellular IDO expression in DC. Data are representative of 3 experiments. Intracellular
IDO expression was given by a one-tailed two sampled t-test comparing MFIIDO (dark histograms) and MFIIsotype control (light histograms), where MFI is
the Mean Fluorescence Intensity. Left: In vitro immatured DC (p=0.100). Right: In vitro matured DC (p=0.001). (c), Lysis of autologous CD14
+
monocytes, CD3
+ T cells and CD19
+ B cells isolated directly ex vivo from IDO
+ PBMC, and lysis of autologous CD14
+ monocytes, CD3
+ T cells and
CD19
+ B cells after IFN-c treatment. As a control, we used in vitro generated autologous IDO
- immatured DC and IDO
+ matured DC. (d), Examples of
HLA-A2 restricted T-cell responses against EBV BMLF1280-288 (GLCTLVAML) as measured by ELISPOT in PBMC from a breast cancer patient. Cultures of
PBMC were treated with IFN-c for 5 days with autologuous freshly isolated CD8 T-cells (left) or with autologous IDO5 specific T-cells (at a PBMC:IDO5
specific T-cell ratio of 300:1) (right) before examination for reactivity against the HLA-A2 restricted epitope from EBV BMLF1280-288 (GLCTLVAML).
Three different PBMC concentrations were examined; 1,5610
5 cells, 5610
4 cells (two top rows) and 10
4 cells (bottom two rows).
doi:10.1371/journal.pone.0006910.g006
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from unrelated tumor types, i.e. melanoma, renal cell carcinoma
and breast cancer but not in healthy individuals. These naturally
occurring T-cell responses in cancer patients could be readily
visualized by flow cytometry using HLA/peptide tetramers after in
vitro stimulation but even more remarkable in direct ex vivo assays.
In this regard, it should be noted that with a few exceptions it is
not possible to detect conventional tumor associated antigen
specific T cells in PBMC from cancer patients directly ex vivo, i.e.
without any in vitro steps to expand or enrich these cells [32]. Thus,
in some cancer patients IDO-specific T cells are present in relative
high frequencies. We further reveal that IDO-specific T cells
readily can be detected in the tumor microenvironment in lesions
from both head and neck cancers and melanoma using tetramer
stainings as well as ELISPOT. The combined detection of IDO-
specific T cells in blood and tumor lesions indicate that these cells
are capable of circulating and homing to the effector site. This is a
significant finding, since several clinical reports have indicated the
existence of a functional dissociation between local and systemic
anti-cancer T-cell responses [36,37].
Furthermore, we confirm that IDO-reactive T cells are indeed
peptide specific, cytotoxic effector cells. Hence, an important issue
concerning translation of our findings to a clinical setting lies in
demonstrating the cytotoxic capacity of IDO-specific T cells against
clinically relevant target cells. In this regard, IDO-specific T cells
effectively lysed IDO
+ cancer cell lines of different origin, such as
melanoma, colon carcinoma, and breast cancer. Most importantly,
leukaemia cells enriched directly from AML patients were killed ex
vivo by IDO-specific T cells. IDO expression in blasts of AML
patients have been correlated to significantly shorten overall and
relapse-free survival [38]. The presence of spontaneous T-cell
responses against IDO-derived peptide epitopes in PBMC from
patients sufferingfrom unrelated cancertypesaswell asthekilling of
cancer cells of different origin by IDO-specific T cells underline the
immunotherapeutic potential of IDO. The induction of IDO
expression after in vitro maturation of DC might be a major problem
and an explanation for the lack of success of DC-based
immunotherapy. However, even more distinctive was our finding
that IDO-specific CTL recognize and kill IDO
+ in vitro matured
DC; hence, IDO-specific T cells are indeed able to kill immune
suppressive cells. It is well described that IDO is up regulated in DC
in tumor draining LN creating a tolerogenic microenvironment.
Furthermore, DC isolated from cancer patients has impaired
functionality and possesses an altered phenotype compared to
healthy individuals. Hence, IDO vaccination might restore the
ability of DC in cancer patients to initiate and/or activate anti-
cancer immune responses by killing immune competent DC.
Counter-regulatory responses are important in the immune
system as they help to limit the intensity and extent of immune
responses, which otherwise could cause dangerous damage to the
host. However, with regard to anti-cancer immunotherapy
counter-regulatory responses antagonize the ability to create an
intense immune response against the tumor. Counter-regulation
differs from tolerance in the sense that counter-regulation is a
secondary event, elicited only in response to immune activation.
By definition most anti-cancer immunotherapeutic strategies
irrespective of their molecular targets aim at the induction of an
immunological activation and inflammation. Virtually, within the
limits of acceptable toxicity as much immune activation as possible
is the goal; hence, counter-regulation is not desired. IDO may be
highly relevant to the outcome of immunotherapy of cancer as an
inflammation-induced counter-regulatory mechanism. Hence,
IDO is known to be induced by both type I and II interferons,
which are found at sites of immune activation and inflammation
[39,40]. In this regard, we demonstrated that that the susceptibility
of tumor cells to killing by IDO-reactive T cells is increased by
preincubation with IFN-c although this increased recognition
might also be due to higher expression of HLA on the surface after
IFN-c treatment. Furthermore, we included a model where the
addition of IDO specific T cells to IFN-c treated PBMC increased
the immune reactivity towards EBV. Hence, our findings suggest
that IDO-based immunotherapy would work synergistically with
additional therapy that introduces inflammation at the site of the
tumor. Additionally, we illustrate that down-regulation of IDO
rescue tumor cells from being killed by IDO-specific T cells. In this
regard, immunoselection of antigen-loss variants during immuno-
therapy have been demonstrated in several cases [36,41–44].
Accordingly, down regulation of IDO during IDO-based immu-
notherapy might save cancer cells and immune suppressive cells
for immune-mediated destruction by IDO-specific CTL. This
should, however, lead to removal of local immune suppression
within the tumor and/or tumor draining LN and thereby enabling
circulating effector cells to function or to get activated.
The state of lymphopenia following high-dose chemotherapy
appears to provide a window of enhanced responsiveness to
immunotherapy [45]. Additionally, certain chemotherapeutic
drugs may assist in breaking immune tolerance by preferentially
inhibition of Tregs [46,47]. Nonetheless, chemotherapy alone is
never sufficient to break tolerance to tumors probably because the
original tolerogenic mechanisms rapidly restore tolerance follow-
ing each cycle of chemotherapy. In principle, therefore, chemo-
therapy might provide an environment in which IDO-based
immunotherapy could have a synergistic effect on established
tumors, by preventing the re-acquisition of tolerance. This is
supported by the report that the IDO blocker 1-Methyl-
Tryptophan (1-MT) work synergistically with different chemo-
therapy drugs in established murine cancers [17].
In conclusion, we demonstrate that IDO is a natural target for
CTL in cancer patients. Thus, we describe that although IDO up
regulation has an immune suppressive effect in cancer, the
immune system – at least in some patients - finds a way to fight
back; by the induction of IDO-specific CTL. The immune
dysfunction in the draining LN due to local IDO expression in DC
is not indicative of a generalized immune suppression in cancer
patients. Subsequently, it may well be possible to strengthen the
described natural immunity against IDO by active immunother-
apy. Since IDO-expressing cells might antagonize the desired
effects of other immunotherapeutic approaches targeting IDO-
expressing cells by vaccination would consequently be highly
synergistic with such therapeutic measures. Finally, the recent
ability of genetically modifying lymphocytes has opened possibil-
ities for the in vitro creation of specific lymphocytes with
appropriate therapeutic properties. Hence, the IDO T-cell
receptors isolated from the T-cell clones described in the current
manuscript can be introduced into a patient’s normal lymphocytes
and administered to lymphodepleted patients as described for
other antigens [45,48–50].
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